MedinCell S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MedinCell S.A. develops and licenses long-acting injectable therapies using its proprietary BEPO technology platform, which enables controlled drug delivery for days, weeks or months from a single subcutaneous or local bioresorbable injection; core products include UZEDY (risperidone subcutaneous extended-release injection for schizophrenia, approved by the FDA in 2023 and marketed by Teva Pharmaceuticals in the United States with approvals in Canada and South Korea in 2025), olanzapine long-acting injectable (mdc-TJK/TEV-749 with Teva, Phase 3 completed with positive results showing no post-injection delirium/sedation syndrome and NDA submission planned for Q4 2025), celecoxib intra-articular injection (mdc-CWM with Arthritis Innovation Corporation, Phase 3 ongoing for post-operative pain after total knee replacement), and earlier-stage programs such as a subcutaneous contraceptive (mdc-WWM) and malaria prevention therapies (mdc-STM) in partnership with global health organizations including Unitaid and Medicines Patent Pool. The company operates in the biotechnology sector across therapeutic areas including psychiatry, pain management, reproductive health, infectious diseases and global health, targeting patients worldwide through partnerships with pharmaceutical firms, biotech companies and non-governmental organizations; it conducts research and development in-house and via collaborations, with geographic focus on Europe, North America and emerging markets. Founded in 2003 and headquartered in Jacou, France, MedinCell employs approximately 140 people and lists on Euronext Paris (MEDCL). Recent developments include a strategic co-development and licensing agreement with AbbVie in April 2024 to advance up to six long-acting injectables across multiple therapeutic areas (first program in preclinical stage since September 2024, $35 million upfront and up to $1.9 billion in milestones plus royalties), a successful €43 million global offering in February 2025 led by investors including Adage Capital, Invus, Polar Capital and Wellington Management to expand BEPO into new molecules/indications and strengthen the balance sheet, positive Phase 3 results and US NDA preparations for olanzapine LAI with Teva amid strong UZEDY sales growth (2025 outlook raised to $190-200 million), new Phase 3 data for mdc-CWM, a grant award in November 2025 to advance malaria programs, and creation of US subsidiary MedinCell Inc.
Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory
MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript
Medincell Reports FY 2025-26 Annual Results
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MedinCell S.A. (MDCLF) Q2 2026 Earnings Call Transcript